11.2.2 Übersichtsartikel/Reviews 1. Distler JHW, Wenger RH, Gassmann M, Kurowska M, Hirth A, Gay S, Distler O: Physiologic responses to hypoxia and implica- tions for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 50:10-23, <strong>2004</strong>. 2. Uebelhart D, Frey D, Frey-Rindova P, Goeres G, Michel BA: Osteoporosebehandlung: Biphosphonate, SERM's, Teriparatide und Strontium. Z Rheumatol 62:512-517, <strong>2004</strong>. 3. Gay S, Michel BA: Was haben wir in der Diagnostik und Therapie in der Zukunft zu erwarten? Med Spektrum 14:37-38, <strong>2004</strong>. 4. Grob D, Daehn S, Mannion A: Titanium mesh cages (TMC) in spine surgery. Eur Spine J: Online ahead on publication, 31 Au- gust: 10.1007/s00586-004-0748-7, <strong>2004</strong>. 5. Junge A, Mannion A: Questionnaires in the evaluation and outcome of assessment of patients with low back pain. Orthopade 33(5):545-552, <strong>2004</strong>. 6. Niedermann K, Fransen J, Knols R, Uebelhart D: Gap between short- and long-term effects of patient education in rheumatoid arthritis patients: a systematic review. Arthritis Rheum 51:388-398, <strong>2004</strong>. 7. Judex M, Neumann E, Gay S, Müller-Ladner U: Laser-mediated microdissection as a tool for molecular analysis in arthritis. Me- thods Mol Med 101:93-106, <strong>2004</strong>. 8. Huber LC, Pap T, Müller-Ladner U, Gay RE, Gay S: Gene targeting: roadmap to future therapies. Curr Rheumatol Rep 6(5):323-325, <strong>2004</strong>. 9. Ospelt C, Neidhart M, Gay RE, Gay S: Synovial activation in rheumatoid arthritis. Front Biosci 9:2323-2334, <strong>2004</strong>. 10. Weber M, Brühlmann P: Ersatz topischer nichtsteroidaler Antirheumatika bei rheumatischen Erkrankungen. Med 7:14-16, <strong>2004</strong>. 11. Niedermann Karin Fransen Jaap Knols Rudolf Uebelhart Daniel Gap between short- and long-term effects of patient education in rheumatoid arthritis patients: a systematic review. Arthritis Care Res <strong>2004</strong>;51(3):388-98 12. Junge A Mannion Anne F.Questionnaires in the evaluation and outcome assessment of patients with low back pain. Orthopade <strong>2004</strong>;33(5):545-552 13. Uebelhart D, Frey D, Frey-Rindova P, Goeres G, Michel BA: Osteoporosebehandlung: Biphosphonate, SERM's, Teriparatide und Strontium. Z Rheumatol 62:512-517, <strong>2004</strong> 14. Koelz HR, Michel BA: Nichtsteroidale Antirheumatika: Magenschutztherapie oder COX-2-Hemmer? Deutsches Aerzteblatt 45:3041-3046, <strong>2004</strong> 11.2.6 Beiträge in Kongress-, Tagungs- und Workshopbänden (Proceedings) 1. Kurowska-Stolarska M, Distler J, Pap T, Jüngel A, Moritz W, Gay S, Michel BA, Gay RE, Maslinski W, Distler O. The inhibitor of helix-loop-helix transcription factor ID-2 triggered by hypoxia and proinflammatory cytokines promiotes the activated phenotype of synovial fibroblasts facilitating bone degradation. Ann Rheum Dis, 63 (Supl 1):79, <strong>2004</strong> 2. Distler J, Jüngel A, Kowal-Bielecka O, Sprott H, Michel BA, Gay RE, Matucci-Cerinic M, Kalden J, Müller-Ladner U, Lorenz H, Gay S, Distler O. Overexpression of IL-21 receptor mRNA in the epidermis of patients with SSc: lessons from the SCID mouse transplantation model. Ann Rheum Dis, 63 (Supl 1):107, <strong>2004</strong> 3. Kowal-Bielecka O, Kowal K, Distler O, Rojewska J, Bodzenta-Lukaszyk A, Gay RE, GayS, Sierakowski S. 5-LOX and 15-LOX- derived eicosanoids in bronchoalveolar lavaga fluid from patients with scleraderma lung disease: a dysbalance between pro- and antiinflammatory lipid mediators. Ann Rheum Dis, 63 (Supl 1):335, <strong>2004</strong> 4. Curti MN, Oglivie A, Salzmann B, Michel BA, Gay RE, Gay S, Sprott H. Expression and detection of nitric oxide and substance P in blood of patients with chronic low back pain: modulatory effects of Ibuprofen arginine. Ann Rheum Dis, 63 (Supl 1):428, <strong>2004</strong> 5. Felleiter P, Koligi K, Schmet M, Gay RE, Michel BA, Sprott H. Quantitative and semi-quantitative measurement of procalcitonin concentrations in the serum of patients with rheumatoid arthritis. Ann Rheum Dis, 63 (Supl 1):467, <strong>2004</strong> 28
6. Neumann E, Gay S, Werner S, Grifka J, Riepl B, Gay RE, Schölmerich J, Müller-Ladner U. Rheumatoid arthritis synovial fibro- blasts are differentially regulated ba antagonists activin and follistatin. Ann Rheum Dis, 63 (Supl 1):132, <strong>2004</strong> 7. Ehling A, Schäffler A, Neumann E, Tarner IH, Grifka J, Herfarth H, Gay S, Schölmerich J, Müller-Ladner U. Inhibition of the TNF-alfa results in the downregulation of adiponectin-induced IL-6 and MMP-1 synthesis in rheumatoid arthritis and osteoarthri- tis synovial fibroblasts. Ann Rheum Dis, 63 (Supl 1):133, <strong>2004</strong> 8. Müller-Ladner U, Neumann E, Talabot-Ayer D, Pap T, Grifka J, Kullmann F, Schölmerich J, Arend WP, Gay S, Gabay C. Effects of different forms of IL-1RA on cartilage degradation in the SCID mouse gene transfer model for rheumatoid arthritis. Ann Rheum Dis, 63 (Supl 1):147, <strong>2004</strong> 9. Ospelt C, Kurowska-Stolarska M, Neidhart M, Michel BA, Simmen BR, Gay RE, Gay S. Licofelone, a cyclooxygenase/5- lipooxygenase inhibitor reduces expression of IP-10 in RASF. Arthr Rheum 50:S570, <strong>2004</strong> 10. Distler JHW, Jüngel A, Seemayer CA, Gay RE, Michel BA, Gay S, Pisetsky DS, Distler O. Microparticles derived from activated and apoptotic inflammatory cells induce expression of MMPs and inflammatory cytokines by synovial fibroblasts. Arthr Rheum 50:S150, <strong>2004</strong> 11. Neumann E, Riepl B, Werner S, Distler O, Gay RE, Grifka J, Gay S, Schölmerich J, Müller-Ladner U. Molecular effects of activin A and ist antagonist follistatin on RA fibroblasts. Arthr Rheum 50:S153, <strong>2004</strong> 12. Brentano F, Schorr O, Simmen BR, Michel BA, Gay RE, Gay S, Kyburz D. TLR expression profiles of RASF compared to OA and normal skin fibroblasts. Arthr Rheum 50:S517, <strong>2004</strong> 13. Ospelt C, Künzler P, Neidhart M, Michel BA, Simmen BR, Gay RE, Gay S. p38delta induces MMP-3 expression in activated RASF. Arthr Rheum 50:S154, <strong>2004</strong> 14. Pierer M, Brentano F, Wagner U, Häntzschel H, Michel BA, Gay RE, Gay S, Kyburz D. LIGHT induced production of IL-6 and MMPs in RASF and reduced the susceptibility to FAS-induced apoptosis. Arthr Rheum 50:S157, <strong>2004</strong> 15. Neidhart M, Jüngel A, Comazzi M, von Knoch R, Ospelt C, Simmen BR, Michel BA, Gay RE, Gay S. Deficient expression of in- terleukin-10 receptor alfa-chain in RA synovium - limitation of inflammatory animal models. Arthr Rheum 50:S112, <strong>2004</strong> 16. Schorr O, Brentano F, Simmen BR, Michel BA, Gay RE, Gay S, Kyburz D. Differential expression of TLRs and MMPs in TLR- ligand stimulated RASF. Arthr Rheum 50:S156, <strong>2004</strong> 17. Distler JHW, Hueber AJ, Reich III CF, Gay S, Distler O, Pisetsky DS. The release of microparticles by dead and dying cells and their effects on macrophages. Arthr Rheum 50:S330, <strong>2004</strong> 18. Ehling A, Schäffler A, Herfarth H, Grifka J, Distler O, Tarner IH, Distler J, Gay S, Paul G, Schölmerich J, Neumann E, Müller- Ladner U. Adipocytokine-dependent synthesis of IL-6 and MMP-1 in RASF is regulated by p38 MAP kinase and TNF-inhibitors. Arthr Rheum 50:S150, <strong>2004</strong> 19. Cinski A, Meinecke I, Franssen L, Wille A, Pap G, Neumann W, Gay S, Pap T. Gene transfer of siRNA reveals pro-apoptotic ef- fects of the transcriptional represor DAXX in RASF. Arthr Rheum 50:S151, <strong>2004</strong> 20. Forster A, Coluccia D, Wolf O, Kollias S, Hock C, Nitsch RM, Gay S, Michel BA, de Quervain DJ-F. Memory impairment under chronic low-dose glucocorticoid treatment is reversible after discontinuement of the treatment. Arthr Rheum 50:S566, <strong>2004</strong> 21. Wille A, Meinecke I, Franssen L, Cinski A, Pap G, Neumann W, Hay R, Ink B, Gay S, Pap T. The small ubiquitin-like modifier SUMO-1 contributes to the resistance of prosthesis-loosening fibroblasts (PLF) against FasL-induced apoptosis. Arthr Rheum 50:S138, <strong>2004</strong> 22. Drynda A, Quax PHA, van der Laan W, Neumann M, Pap G, Machner A, Drynda S, Kekow J, Neumann W, Gay S, Pap T. Gene transfer with TIMP-3 facilitates apoptosis and reverses the anti-apoptotic effects of TNF-alpha in RA-SF. Arthr Rheum 50:S245, <strong>2004</strong> 23. Neumann E, Tarner IH, Schedel J, Distler O, Pap T, Robbins PD, Grifka J, Gay RE, Evans CH, Schölmerich J, Gay S, Müller- Ladner U. RASF coimplanted with normal human cartilage exert destructive effects on cartilage implanted without cells at dis- tant sites in the SCID mouse model for RA. Arthr Rheum 50:S456, <strong>2004</strong> 29
- Seite 1 und 2: Rheumaklinik und Institut für Phys
- Seite 3 und 4: Das Zentrum bildet neu 2 PhD-Studen
- Seite 5 und 6: Functional analysis of novel drug i
- Seite 7 und 8: 3.2 Qualitätssicherung in der Lehr
- Seite 9 und 10: Stiftungsratsmitglied Rheuma- und R
- Seite 11 und 12: - Ergonomie/Arbeit - Schmerz - Oste
- Seite 13 und 14: Lecture, “Toll-like receptors - N
- Seite 15 und 16: - Lecture, „Konservative Arthrose
- Seite 17 und 18: Circolo medico di Locarno e dintorn
- Seite 19 und 20: -Lecture, "Unnötigen physikalische
- Seite 21 und 22: Invited lectures given by Mahsa Hei
- Seite 23 und 24: Cieza Alarcos, Dr. phil., MPH, Univ
- Seite 25 und 26: 11.2 Unselbstständige Literatur 11
- Seite 27: 29. Morf S, Amann-Vesti B, Forster
- Seite 31 und 32: 41. Mannion AF, Dvorak J, Junge A,
- Seite 33 und 34: 171,60 17,30 1,00 189,90 9,20 04.05
- Seite 35 und 36: 04.05.2005/hz 0,6 2,1 2,7 Universit
- Seite 37 und 38: 04.05.2005/hz 18,0 100,0 0,0 1,0 10